Search
Research
Investigation of group A Streptococcus immune responses in an endemic setting, with a particular focus on J8We analysed the stimulation of J8 antibodies in response to infection, and the role of existing J8 antibodies in protection against subsequent infection
Research
Risk factors for multidrug-resistant tuberculosis in northwest Ethiopia: A case–control studyThe aim of this study was to describe the characteristics of patients with multidrug-resistant tuberculosis and to investigate risk factors
Research
Antibiotic duration and timing of the switch from intravenous to oral route for bacterial infections in children: systematic review and guidelinesSystematic review of antibiotic duration and timing of intravenous to oral switch for paediatric infectious diseases and evidence-graded recommendations
Research
Towards a PBMC "virogram assay" for precision medicine: Concordance between ex vivo and in vivo viral infection transcriptomesIn this rhinovirus study, we first hypothesized that ex vivo human cells response to virus can serve as a proxy for otherwise controversial in vivo human...
Research
A retrospective study of Babesia macropus associated with morbidity and mortalityThis is a retrospective study of 38 cases of infection by Babesia macropus, associated with a syndrome of anaemia and debility in hand-reared or free-ranging...
Research
The global epidemiology of impetigo: A systematic review of the population prevalence of impetigo and pyodermaWe conducted a comprehensive, systematic review of the global childhood population prevalence of impetigo and the broader condition pyoderma.
Research
Efficacy thresholds and target populations for antiviral COVID-19 treatments to save lives and costs: a modelling studyIn 2023 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was declared endemic, yet hospital admissions have persisted and risen within populations at high and moderate risk of developing severe disease, which include those of older age, and those with co-morbidities. Antiviral treatments, currently only available for high-risk individuals, play an important role in preventing severe disease and hospitalisation within this subpopulation.
Research
Nirsevimab binding-site conservation in respiratory syncytial virus fusion glycoprotein worldwide between 1956 and 2021: an analysis of observational study sequencing dataNirsevimab is an extended half-life monoclonal antibody to the respiratory syncytial virus (RSV) fusion protein that has been developed to protect infants for an entire RSV season. Previous studies have shown that the nirsevimab binding site is highly conserved. However, investigations of the geotemporal evolution of potential escape variants in recent (ie, 2015–2021) RSV seasons have been minimal.
News & Events
New meningococcal strains bring increased risk in WAA new study has confirmed the changing pattern of meningococcal disease in Western Australia.
News & Events
Universal protocols for Strep A surveillance set to transform research for world-first vaccineA global consortium of Group A Streptococcus (Strep A) researchers has launched a series of best practice surveillance protocols designed to unite international research efforts for a world-first Strep A vaccine.